Last reviewed · How we verify
Advanced Non-small Cell Lung Cancer With Chinese Medicine Comprehensive Treatment Plan (TCM)
The purpose of this study is to observe the efficacy of chemotherapy combined with Chinese patent drugs for patients with advanced non-small-cell lung cancer, also to evaluate the adverse reaction and the reliability.
Details
| Lead sponsor | Shanghai University of Traditional Chinese Medicine |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | UNKNOWN |
| Enrolment | 120 |
| Start date | 2014-09 |
| Completion | 2019-12 |
Conditions
- Cancer
Interventions
- JinFuKang
- XingZaoRuanJian
- pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin
Primary outcomes
- Progression-Free Survival — From date of randomization until the date of first documented progression or date of death from any cause，up to 2 months
The progression disease is assessed based on CT every 2 months from date of randomization and the endpoints is the date of first documented progression or date of death due to lung cancer.